Recent Publications (2010-2011)

New Drug Targets for Cardiovascular Diseases

Hulot JS, Fauconnier J, Ramanujam D, Chaanine A, Aubart F, Sassi Y, Merkle S, Cazorla O, Dupus M, Hadri L, Jeong D, Muehlstedt S, Braun A, Saliba Y, Laggerbauer B, Nieswandt B, Lachampagne, Hajjar R, Lompre AM, Engelhardt S. A critical role for STIM1 in cardiac hypertrophy. Circulation; 2011: 124:796-805

Hara Y, Sassi Y, Guibert C, Gambaryan N, Dorfmuller P, Eddahibi S, Lompre AM, Humbert M, Hulot JS. Inhibition of ABCC4 (MRP4) prevents and reverts pulmonary hypertension in mice. Journal of Clinical Investigations 2011; 121:2888-97

Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, Fauret AL, Fiessinger JN, Germain DP, Georgesco G, Hulot JS, De Paepe A, Plauchu H, Jeunemaitre X, Laurent S, Boutouyrie P. Effect of Celiprolol on prevention of cardiovascular events in Ehlers-Danlos type IV, the vascular type. Lancet, 2010;376:1476-84

Sassi Y, Abi-Gerges A, Fauconnier J, Mougenot N, Reiken S, Haghighi K, Kranias E, Marks AR, Lachampagne A, Engelhardt S, Hatem SN, Lompre AM, Hulot JS. Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes. FASEB In press


Cayla G & Hulot JS, O’Connor S, Pathak A, Scott S, Gruel Y, Silvain J, Vignalou JB, Huerre Y, De La Briolle A, Allanic F, Beygui F, Barthelemy O, Montalescot G, Collet JP. Clinical, angiographic and genetic determinants of early stent thrombosis in patients on dual antiplatelet therapy: the ONASSIST study. JAMA 2011; 306:1765-74

Hulot JS & Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Apaix A, Scott S, Montalescot G. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics and clinical efficacy in post-myocardial infarction patients. Circulation Cardiovasc Interv; 2011: 4:422-8

Scott S, Sangkuhl K, Shuldiner A, Hulot JS, Thorn C, Klein T, Altman R. PharmGKB summary: cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenetics & Genomics, In press

Scott S, Sangkuhl K, Gardner E, Stein C, Hulot JS, Johnson J, Roden D, Klein T, Shuldiner A. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clinical Pharmacology & Therapeutics 2011; 90:328-32

Hulot JS, Hajjar RJ, Montalescot G. Clopidogrel and CYP2C19 genetic testing: ready for prime time? Clinical Chemistry 2011, In press

Silvain J, Pena A, Vignalou JB, Hulot JS, Gallier S, Cayla G, Bellemain-Appaix A, Barthelemy O, Beyguif, Bal Dit Sollier C, Drouet L, Weisel JW, Montalescot G, Collet JP. Effect of FXIII Leu34 genetic variant on premature coronary artery disease, fibrin clot structure/function and response to fibrinolysis. Thrombosis and Haemostasis; 2011; 106:511-20

Collet JP, Hulot JS, Anzaha G, Pena A, Chastre T, Caron C, Silvain J, Cayla G, Bellemain-Appaix A, Vignalou JB, Galier S, Barthelemy O, Beygui F, Gallois V, Montalescot G.High doses of clopidogrel to overcome genetic resistance: The randomized crossover CLOVIS-2 (Clopidogrel and Response variability investigation Study 2). J Am Coll Cardiol Intv 2011; 4:392-402

Mega J, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. isk of Adverse Clinical Outcomes with Even One Reduced-Function CYP2C19 Allele in Patients Treated with Standard Doses of Clopidogrel. JAMA 2010; 304:1821-30

Hulot JS, Collet JP, Silvain J, Pena A, Bellemain A, Barthelemy O, Cayla G, Beygui F, Montalescot G. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor co-administration: a systematic meta-analysis. Journal of American College of Cardiology 2010; 56:134-43

Hulot JS, Wuerzner G, Bachelot-Loza C, Villard E, Azizi M, Dali Ali F, Blanchard A, Vrignaud C, Peyrard S, Funck-Brentano C, Gaussem P.Effect of an increased clopidogrel maintenance dose and of lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects. J Thromb Haemost 2010; 8:610-3